NHS to Offer Weight-Loss Drugs to Millions: A Comprehensive Guide
NHS Expands Access to Weight-Loss Medications
Millions of people in the UK will soon have access to weight-loss drugs through the NHS to help manage obesity-related health conditions. While Wegovy is already available to some patients, a second drug, Mounjaro, will be introduced in 2025. However, full-scale rollout may take over a decade due to high demand and resource constraints.
How Do Wegovy and Mounjaro Work?
Two weight-loss drugs currently available are:
Wegovy (Semaglutide): Also used for type 2 diabetes treatment under the brand name Ozempic.
Mounjaro (Tirzepatide): A newer drug with promising weight-loss effects.
Both drugs are administered as weekly injections using pre-filled pens. They work by mimicking glucagon-like peptide-1 (GLP-1), a hormone that suppresses appetite. Mounjaro also impacts another hormone, glucose-dependent insulinotropic polypeptide (GIP), which enhances metabolism and energy balance.
How Much Weight Can Patients Lose?
Clinical trials suggest significant weight-loss potential:
Wegovy users may lose over 10% of their body weight within a year when combined with diet and exercise.
Mounjaro users could achieve even greater results, with some losing up to 20% of their body weight.
However, it is important to note that weight may be regained once patients stop taking the medication.
Who Qualifies for NHS Weight-Loss Treatment?
Currently, only Wegovy is available through the NHS in England, Wales, and Scotland, prescribed by weight management specialists.
Eligibility Criteria:
A BMI of at least 35.
At least one weight-related health condition (e.g., high blood pressure or cardiovascular disease).
Overweight individuals with heart conditions may also qualify, even if their BMI is below 35.
The drug should be used for a maximum of two years, alongside a supervised diet and exercise plan.
From March 2025, Mounjaro will be introduced under similar eligibility criteria. By June 2025, it will become more widely available, but details on the rollout process are still pending.
NHS Rollout Plans:
Up to 3.4 million people could qualify for Mounjaro treatment.
Due to high demand, full access may take over a decade.
300,000 patients are expected to benefit within the first three years.
Additionally, the UK government is considering offering weight-loss injections to unemployed individuals with obesity, citing potential economic and health benefits.
Private Access & Cost of Weight-Loss Injections
For those who do not qualify for NHS prescriptions, Wegovy and Mounjaro are available privately in pharmacies, supermarkets, and high-street clinics.
Prices range from £200 to £300 per pen, depending on the dosage.
Buyers should be cautious of unregulated online sellers and beauty salons offering semaglutide without proper prescriptions.
To combat misuse, new regulations (February 2025) require online pharmacies to conduct stricter checks, including in-person or video consultations and verified BMI records.
Side Effects & Risks of Weight-Loss Injections
Common Side Effects:
Nausea
Vomiting
Bloating
Constipation
Diarrhea
Hair loss (in some cases)
Most side effects subside over time, but serious complications (such as gallbladder issues, kidney problems, or depression) have been reported. Doctors warn that misuse, especially buying from unregulated sources, can lead to life-threatening conditions like pancreatitis.
What Happens After Stopping Weight-Loss Drugs?
Studies show that most users regain weight within a year of stopping treatment. To maintain weight loss, experts recommend sustainable lifestyle changes, including a balanced diet and regular exercise.
Understanding BMI & Obesity
Obesity is defined as excessive body fat, affecting 1 in 4 UK adults. BMI (Body Mass Index) is commonly used to categorize weight levels:
| BMI Range | Category |
|---|---|
| Below 18.5 | Underweight |
| 18.5 - 24.9 | Healthy Weight |
| 25 - 29.9 | Overweight |
| 30 - 39.9 | Obese |
| 40+ | Severely Obese |
For people of Asian, Chinese, Middle Eastern, Black African, or African-Caribbean descent, lower BMI thresholds apply:
23 - 27.4: Overweight
27.5+: Obese
Final Thoughts
While weight-loss drugs like Wegovy and Mounjaro offer promising results, they should be part of a long-term health strategy, not a quick fix. The NHS is working to expand access, but demand remains high, making private options an alternative for some individuals. Always consult a medical professional before starting any weight-loss treatment.
